In vivo ERK½ reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma

Combined BRAF and MEK inhibition is a standard of care in patients with advanced BRAF mutant melanoma but acquired resistance remains a challenge that limits response durability. Here we quantitated in vivo ERK½ activity and tumor response associated with resistance to combined BRAF and MEK inhibiti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer Ther
Hlavní autoři: Sanchez, Ileine M., Purwin, Timothy J., Chervoneva, Inna, Erkes, Dan A., Nguyen, Mai Q., Davies, Michael A., Nathanson, Katherine L., Kemper, Kristel, Peeper, Daniel S., Aplin, Andrew E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726573/
https://ncbi.nlm.nih.gov/pubmed/31270153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-1056
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky